PP
NKTR icon

PFS Partners’s Nektar Therapeutics NKTR Stock Holding History

PFS Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-40
Closed -$338 – 481
2023
Q4 		$338 Hold
40
– – ﹤0.01% 441
2023
Q3 		$356 Hold
40
– – ﹤0.01% 443
2023
Q2 		$344 Hold
40
– – ﹤0.01% 462
2023
Q1 		$420 Hold
40
– – ﹤0.01% 371
2022
Q4 		$1.35K Hold
40
– – ﹤0.01% 337
2022
Q3 		$1.91K Hold
40
– – ﹤0.01% 310
2022
Q2 		$2.27K Hold
40
– – ﹤0.01% 292
2022
Q1 		$3.22K Hold
40
– – ﹤0.01% 287
2021
Q4 		$8.07K Buy
+40
New +$8.68K 0.01% 227

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PFS Partners's NKTR Position: Q1 2024 in Review

PFS Partners sold out of Nektar Therapeutics (NKTR) in Q1 2024, closing a stake of 40 shares — an estimated $338 sold.

PFS Partners first reported a position in NKTR in Q4 2021 and held it in 9 quarters. The position peaked at $8.07K in Q4 2021. 124 funds tracked by Wall St. Rank hold NKTR as of Q1 2024.

  • PFS Partners reported no remaining Nektar Therapeutics position as of Q1 2024 after selling out during the quarter.
  • PFS Partners sold 40 Nektar Therapeutics shares in Q1 2024, an estimated $338.
  • PFS Partners first reported a position in Nektar Therapeutics in Q4 2021 and held it in 9 quarters.
  • PFS Partners's Nektar Therapeutics position peaked at $8.07K in Q4 2021.
  • 124 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2024.

Based on PFS Partners's 13F filing for Q1 2024, filed 15 Apr 2024.